anti-TLR4 (human) mAb (2E11)
Product Code:
IAX-400-003
IAX-400-003
Host Type:
Mouse
Mouse
Antibody Isotype:
Mouse IgG1
Mouse IgG1
Antibody Clonality:
Monoclonal
Monoclonal
Antibody Clone:
2.00E+11
2.00E+11
Regulatory Status:
RUO
RUO
Target Species:
Human
Human
Applications:
- Fluorescence-activated cell sorting (FACS)
- Immunocytochemistry (ICC)
Shipping:
BLUE ICE
BLUE ICE
Storage:
Short Term: +4°C Long Term: -20°C
Short Term: +4°C Long Term: -20°C
No additional charges, what you see is what you pay! *
Code | Size | Price |
---|
IAX-400-003-C100 | 100 ug | £637.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
Toll-like Receptor 4; TOLL; hToll; CD284; ARMD10
Concentration:
1mg/ml
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid. In PBS, sucrose, PEG, 0.09% sodium azide.
Handling Advice:
After opening, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.Keep sterile.
Immunogen:
Recombinant human TLR4.
Long Description:
Monoclonal Antibody. Recognizes the extracellular domain of human TLR4. Does not cross-react with mouse TLR4. Other species not tested. Applications: FACS, ICC. Isotype: Mouse IgG1. Liquid. In PBS, sucrose, PEG, 0.09% sodium azide. TLR4 (Toll-like Receptor 4) is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. It was the first TLR identified TLR in mammals and most studied member of the TLR family. TLR4 recognizes the active lipid A component of lipopolysaccharide (LPS) from Gram-negative bacteria in conjunction with LY96 (also referred to MD-2), CD14 and LPS-binding protein (LBP) and consequently mediates the innate immune response to bacterial lipopolysaccharide (LPS). Additionally, it is also involved in LPS-independent responses triggered by endogenous DMAPs, such as heat shock proteins (HSPs) or HMGB1. TLR4 signals via MYD88, TIRAP and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response in various cell types. In complex with TLR6, it was shown to promote sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. TLR4-mediated inflammation, triggered by exogenous or endogenous ligands, is involved in several acute and chronic diseases, having a pivotal role as amplifier of the inflammatory response. The potency with which this TLR activates inflammatory pathways makes it an ideal target for therapeutic intervention and adjuvant development. A broad range of clinical studies have examined the adjuvant activity of TLR4 activators in vaccines against infectious and tumor antigens. This antibody detects human TLR4 in the absence and presence of MD2 (tested on THP-1 human macrophages). It does not block LPS-mediated activation of human TLR4 (as tested by NFkappaB activation).
NCBI, Uniprot Number:
O00206
Package Type:
Plastic Vial
Product Description:
TLR4 (Toll-like Receptor 4) is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. It was the first TLR identified TLR in mammals and most studied member of the TLR family. TLR4 recognizes the active lipid A component of lipopolysaccharide (LPS) from Gram-negative bacteria in conjunction with LY96 (also referred to MD-2), CD14 and LPS-binding protein (LBP) and consequently mediates the innate immune response to bacterial lipopolysaccharide (LPS). Additionally, it is also involved in LPS-independent responses triggered by endogenous DMAPs, such as heat shock proteins (HSPs) or HMGB1. TLR4 signals via MYD88, TIRAP and TRAF6, leading to NF-kappaB activation, cytokine secretion and the inflammatory response in various cell types. In complex with TLR6, it was shown to promote sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. TLR4-mediated inflammation, triggered by exogenous or endogenous ligands, is involved in several acute and chronic diseases, having a pivotal role as amplifier of the inflammatory response. The potency with which this TLR activates inflammatory pathways makes it an ideal target for therapeutic intervention and adjuvant development. A broad range of clinical studies have examined the adjuvant activity of TLR4 activators in vaccines against infectious and tumor antigens. This antibody detects human TLR4 in the absence and presence of MD2 (tested on THP-1 human macrophages). It does not block LPS-mediated activation of human TLR4 (as tested by NFkappaB activation).
Purity:
>95% (SDS-PAGE)
Source / Host:
Purified from concentrated hybridoma tissue culture supernatant.
Specificity:
Recognizes the extracellular domain of human TLR4. Does not cross-react with mouse TLR4. Other species not tested.
Transportation:
Non-Hazardous
UNSPSC Category:
Primary Antibodies
UNSPSC Number:
12352203
Use & Stability:
Stable for at least 1 year after receipt when stored at -20°C.
Documents
References
TLR4 antagonist FP7 inhibits LPS-induced cytokine production and glycolytic reprogramming in dendritic cells, and protects mice from lethal influenza infection: L. Perrin-Cocon, et al.; Sci. Rep. 7, 40791 (2017)